RMX300 1 (Korean original product code is DHP 107, registered as Liporaxel) is an oral paclitaxel preparation jointly developed by Dahua Pharmaceutical Korea Dahua Company and Korea Institute of Science and Technology (KIST), in which paclitaxel is dissolved in "DH-LASED" (Dahua-lipid-based self-emulsifying drug delivery technology. Using this technology, the main difficulty of low oral bioavailability of paclitaxel was solved by lipid delivery of paclitaxel.

RMX300 1 (foreign code DHP 107) was successfully approved by the US Food and Drug Administration (MFDS) on September 9, 20 16. Indications are advanced and metastatic or local recurrent gastric cancer. This is the first oral paclitaxel product successfully developed and approved for marketing in the world. Patients in need can consult or purchase through formal overseas medical platforms (such as Hong Kong Maijikang Medical Center).

The clinical trial of RMX300 1 (foreign code DHP 107) in the key stage III gastric cancer in Korea shows that compared with paclitaxel injection, RMX 300 1 can significantly reduce the occurrence of adverse reactions of patients, such as peripheral neuropathy, allergic reaction, alopecia and myalgia. In addition, oral administration also avoids adverse reactions such as extravasation and phlebitis that may be caused by intravenous injection.